Ignite Creation Date:
2024-05-06 @ 11:02 AM
Last Modification Date:
2024-10-26 @ 12:39 PM
Study NCT ID:
NCT03417882
Status:
TERMINATED
Last Update Posted:
2023-08-08
First Post:
2017-11-14
Brief Title:
GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1 NSCLC
Sponsor:
BrightPath Biotherapeutics
Organization:
BrightPath Biotherapeutics
Organization Data
Organization:
BrightPath Biotherapeutics
Class:
INDUSTRY
Study ID:
GRN-1201-002
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
BrightPath Biotherapeutics
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None